With its own product for multiple sclerosis and spinal cord injuries already in the works, Acorda Therapeutics Inc. acquired from Elan Corp. plc all U.S. rights to oral Zanaflex (tizanidine), a marketed treatment for spasticity in patients with those conditions. (BioWorld Today)